Skip to main content
. Author manuscript; available in PMC: 2018 Mar 1.
Published in final edited form as: Mol Cancer Ther. 2016 Dec 21;16(3):440–452. doi: 10.1158/1535-7163.MCT-16-0285

Figure 1. Development of synergistically acting CelePlum-777.

Figure 1

(1A). Celecoxib and Plumbagin inhibit the viability of UACC 903 cells in a cooperative manner as measured by MTS assay. Data represent averages of at least 3 independent experiments; bars, S.E.M. (1B). Calcusyn analysis suggest synergistic killing by Celecoxib and Plumbagin and CI values range from 0.74 to 0.83. (1C). Structure of CelePlum-777 showing predicted location of Celecoxib and Plumbagin within the liposome. (1D). Size and charge of CelePlum-777 dissolved in water or saline. Size and zeta potential of empty liposomes, Celecoxib or Plumbagin liposomes alone, or CelePlum-777. Data represent averages of at least 3 independent experiments; bars, S.E.M.